On-demand tickets

Martina Garau
Director | OHE

Associated Masterclass: Exploring Value: Novel Elements for Breakthrough Treatment.

Lecture duration: 05:47

• Exploring the expanded and actionable definition of value
• Discussing how broader value elements resonate with decision makers
• Understanding the practical and policy challenges faced by adopting broader value elements

Professor Adrian Towse
Director Emeritus and Senior Research Fellow | OHE

Associated Masterclass: Exploring Value: Novel Elements for Breakthrough Treatment.

Lecture duration: 17:19

• Exploring a brief history of established sources of value
• Analysing novel value elements and what they entail
• Discussing which value elements should be considered

Martina Garau
Director | OHE

Associated Masterclass: Exploring Value: Novel Elements for Breakthrough Treatment.

Lecture duration: 17:01

• Exploring the need for an aggregation method for multiple value elements
• Outlining the implications of cost effectiveness benchmarks
• Discussing the continuum of decision making approaches from deliberative to quantitative with real-world examples

Patricia Cubi-Molla
Senior Principal Economist | OHE

Associated Masterclass: Patient Outcomes: Measuring What Matters to Patients.

Lecture duration: 18:54

• Public sector spending and research allocation
• Healthcare sector spending through measuring patient preference
• Health technologies spending through measuring outcomes

Dr David Mott
Principal Economist | OHE

Associated Masterclass: Patient Outcomes: Measuring What Matters to Patients.

Lecture duration: 19:35

• Outlining when and how the quality of life of carers should be measured
• Discussing the potential impact of carer quality of life measurement on HTA
• Exploring broader outcome measurements and their scope for use in HTA

Dr Chris Sampson
Principal Economist | OHE

Associated Masterclass: Patient Outcomes: Measuring What Matters to Patients.

Lecture duration: 19:52

• Exploring alternative generic measures for patient outcomes
• Outlining condition-specific measures and their potential advantages
• Introducing bolt-ons methods

Dr Chris Skedgel
Director | OHE

Associated Masterclass: The Patient Voice: Capturing Patient Preferences in Decision-Making.

Lecture duration: 13:40

• Explaining patient preferences in HTA
• Discussing empirical evidence around the role of patient preferences in HTA
• Outlining the future of the patient voice in HTA

Dr David Mott
Principal Economist | OHE

Associated Masterclass: The Patient Voice: Capturing Patient Preferences in Decision-Making.

Lecture duration: 19:57

• Methodologies used to elicit quantitative patient preference data
• The typical stages of a quantitative patient preference study
• The type of insights that can be obtained from quantitative patient preference data

Professor Adrian Towse
Director Emeritus and Senior Research Fellow | OHE

Associated Masterclass: Innovation for Small Populations: What Should We Pay for?

Lecture duration: 20:16

• Is Market Exclusivity (ME) needed to incentivise the Research & Development (R&D) of Orphan Medical Products (OMPs)?
• Are R&D costs for individual OMPs lower than those for medicines for more common conditions?
• What is a fair price for OMPs?

Dr Chris Skedgel
Director | OHE

Associated Masterclass: Innovation for Small Populations: What Should We Pay for?

Lecture duration: 19:32

• Are health conditions been salami-sliced to drive exceptionalism?
• Can evidence in support of Health Technology Assessment (HTA) submissions for OMPs meet the same standards as medicines for more common conditions?
• What is society willingness to prioritise treatments for rare conditions?

Professor Lotte Steuten
Vice President | OHE

Associated Masterclass: Adaptive Pathways: Generating Evidence of Value.

Lecture duration: 22:28

• Elements driving uncertainty at an early stage of a treatment introduction
• Using surrogate endpoints in clinical trials
• How different types of uncertainty can be addressed, including conditional reimbursement schemes

Professor Adrian Towse
Director Emeritus and Senior Research Fellow | OHE

Associated Masterclass: Adaptive Pathways: Generating Evidence of Value.

Lecture duration: 20:55

• Implications of accelerated approval for payer uncertainty
• Application of the value of information approach to inform optimal use of risk sharing schemes
• When companies should actively seek an AP

Isobel Firth
Senior economist | OHE

Associated Masterclass: Adaptive Pathways: Generating Evidence of Value.

Lecture duration: 17:36

• Accelerated Pathways (AP) introduced by the EMA and MHRA
• What APs mean to development and access to medicines
• Examples of early access in Europe